Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Issue 12 (22nd March 2013)
- Record Type:
- Journal Article
- Title:
- Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Issue 12 (22nd March 2013)
- Main Title:
- Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment
- Authors:
- Schubert, Peter
Coupland, Danielle
Culibrk, Brankica
Goodrich, Raymond P.
Devine, Dana V. - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="trf12173-sec-0001" sec-type="section"> <title>Background</title> <p>Pathogen reduction technologies (PRTs) significantly reduce the risk of transmission of infectious agents in platelet (PLT) concentrates; however, in vitro studies reveal a negative impact on PLT quality after PRT treatment including effects on PLT aggregation, integrin αIIbβ3 conformation, and actin dynamics. Clinically, the interval between transfusions is shortened.</p> </sec> <sec id="trf12173-sec-0002" sec-type="section"> <title>Study Design and Methods</title> <p>Seeking to understand the biochemical mechanisms underlying these observed effects, we analyzed signal transduction in PLT concentrates after riboflavin and ultraviolet light (UV; Mirasol) treatment and subsequent storage focusing on the phosphorylation levels of selected protein kinases.</p> </sec> <sec id="trf12173-sec-0003" sec-type="section"> <title>Results</title> <p>Among identified candidates, p38MAPK increased fourfold in phosphorylation after PRT. Incubation of PLT concentrates with a p38MAPK‐specific inhibitor before PRT significantly improved numerous PLT quality measures. Phosphorylation levels of the p38MAPK substrates AKT, VASP, and HSP27 also decreased with inhibitor treatment. Phospho‐HSP27 decrease in the presence of the inhibitor correlated with a reduction in PLT activation determined by surface expression of P‐selectin.</p> </sec><abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="trf12173-sec-0001" sec-type="section"> <title>Background</title> <p>Pathogen reduction technologies (PRTs) significantly reduce the risk of transmission of infectious agents in platelet (PLT) concentrates; however, in vitro studies reveal a negative impact on PLT quality after PRT treatment including effects on PLT aggregation, integrin αIIbβ3 conformation, and actin dynamics. Clinically, the interval between transfusions is shortened.</p> </sec> <sec id="trf12173-sec-0002" sec-type="section"> <title>Study Design and Methods</title> <p>Seeking to understand the biochemical mechanisms underlying these observed effects, we analyzed signal transduction in PLT concentrates after riboflavin and ultraviolet light (UV; Mirasol) treatment and subsequent storage focusing on the phosphorylation levels of selected protein kinases.</p> </sec> <sec id="trf12173-sec-0003" sec-type="section"> <title>Results</title> <p>Among identified candidates, p38MAPK increased fourfold in phosphorylation after PRT. Incubation of PLT concentrates with a p38MAPK‐specific inhibitor before PRT significantly improved numerous PLT quality measures. Phosphorylation levels of the p38MAPK substrates AKT, VASP, and HSP27 also decreased with inhibitor treatment. Phospho‐HSP27 decrease in the presence of the inhibitor correlated with a reduction in PLT activation determined by surface expression of P‐selectin.</p> </sec> <sec id="trf12173-sec-0004" sec-type="section"> <title>Conclusion</title> <p>These findings support a model of one dominant underlying molecular signaling mechanism that is impacted by the riboflavin and UV (Mirasol) PRT process resulting in alterations in PLT quality. The identification of such a target should assist in the development of strategies to ameliorate this negative aspect of an otherwise beneficial and important safety development for transfusion medicine.</p> </sec> </abstract> … (more)
- Is Part Of:
- Transfusion. Volume 53:Issue 12(2013)
- Journal:
- Transfusion
- Issue:
- Volume 53:Issue 12(2013)
- Issue Display:
- Volume 53, Issue 12 (2013)
- Year:
- 2013
- Volume:
- 53
- Issue:
- 12
- Issue Sort Value:
- 2013-0053-0012-0000
- Page Start:
- 3164
- Page End:
- 3173
- Publication Date:
- 2013-03-22
- Subjects:
- Hematology -- Periodicals
Blood -- Transfusion -- Periodicals
Blood Group Antigens -- Periodicals
Blood Preservation -- Periodicals
Blood Transfusion -- Periodicals
615 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1537-2995 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=trf ↗
http://www.transfusion.org ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/trf.12173 ↗
- Languages:
- English
- ISSNs:
- 0041-1132
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9020.704000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3876.xml